The Immunology Podcast cover image

Ep. 29: “Immuno-Oncology Therapeutics” Featuring Dr. Michael Alonso

The Immunology Podcast

00:00

BDC 101 - What's Your Next Step?

BDC 101 is a TLR agonist. It's designed to activate the myeloid cells in tumors that have high levels of them. The goal is to convert these tumor suppressive cells from immune cell fighters to cancer fighters, as we see them in the context of infectious disease. And with the advent of sequencing technology, those patients are now being able to take advantage of some of these her two targeted therapies. We're certainly very interested in those indications.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app